Emerging treatment options for management of malignant ascites in patients with ovarian cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• BookmanMTrials with impact on clinical management: first lineInt J Gynecol Cancer200919Suppl 2S55S6219955916
   PubMed Web of Science ®Google Scholar
• OzolsRBundyBGreerBPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• MonkBChoiDPugmireGBurgerRActivity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecol Oncol200596390290515721449
   PubMed Web of Science ®Google Scholar
• CannistraSEvaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?J Clin Oncol201028193101310320516442
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEWagnerUAavall-LundqvistEPegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol201028203323332920498395
   PubMed Web of Science ®Google Scholar
• CannistraSIs there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?J Clin Oncol20022051158116011870154
   PubMed Web of Science ®Google Scholar
• EskanderRNRandallLMBevacizumab in the treatment of ovarian cancerBiologics201151521383911
   PubMedGoogle Scholar
• MalayevYLeveneRGonzalezFPalliative chemotherapy for malignant ascites secondary to ovarian cancerAm J Hosp Palliat Care2232012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• LoggieBWPeriniMFlemingRARussellGBGeisingerKTreatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapyAm Surg19976321371439012427
   PubMed Web of Science ®Google Scholar
• BarniSCabidduMGhilardiMPetrelliFA novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascitesCrit Rev Oncol Hematol201179214415320708947
   PubMed Web of Science ®Google Scholar
• JemalASiegelRXuJWardECancer Statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• BeckerGBlumHEVEGF trap for the treatment of malignant ascitesLancet Oncol201213211511622192728
   PubMed Web of Science ®Google Scholar
• GarrisonRNGallowayRHHeuserLSMechanisms of malignant ascites productionJ Surg Res19874221261322434730
   PubMed Web of Science ®Google Scholar
• AdamRAAdamYGMalignant ascites: past, present, and futureJ Am Coll Surg20041986999101115194082
   PubMed Web of Science ®Google Scholar
• QaziRSavlovEDPeritoneovenous shunt for palliation of malignant ascitesCancer19824936006026174196
   PubMed Web of Science ®Google Scholar
• ArielIMOropezaRPackGTIntracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patientsCancer1966198109611025912325
   PubMed Web of Science ®Google Scholar
• RunyonBACare of patients with ascitesN Engl J Med199433053373428277955
   PubMed Web of Science ®Google Scholar
• GotliebWHFeldmanBFeldman-MoranOIntraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancerGynecol Oncol19987133813859887235
   PubMed Web of Science ®Google Scholar
• BeckerGGalandiDBlumHEMalignant ascites: systematic review and guideline for treatmentEur J Cancer200642558959716434188
   PubMed Web of Science ®Google Scholar
• KeenAFitzgeraldDBryantADickinsonHOManagement of drainage for malignant ascites in gynaecological cancerCochrane Database Syst Rev20101CD00779420091648
   PubMed Web of Science ®Google Scholar
• StarkRHSauterKESurgical treatment of adenocarcinoma of the stomach in a community hospitalSurg Gynecol Obstet198516021531563969612
   PubMedGoogle Scholar
• OstrowskiMJHalsallGMIntracavitary bleomycin in the management of malignant effusions: a multicenter studyCancer Treat Rep19826611190319076182995
   PubMedGoogle Scholar
• MaatBOosterleeJSpaasJAWhiteHLammesFBDissemination of tumour cells via LeVeen shuntLancet19791812398887670
   PubMed Web of Science ®Google Scholar
• PaladineWCunninghamTJSponzoRDonavanMOlsonKHortonJIntracavitary bleomycin in the management of malignant effusionsCancer19763851903190862609
   PubMed Web of Science ®Google Scholar
• BurgerRAAntiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancerAnn Oncol201122Suppl 8viii65viii6822180405
   PubMedGoogle Scholar
• BurgerRAOverview of anti-angiogenic agents in development for ovarian cancerGynecol Oncol2011121123023821215996
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF as a therapeutic target in cancerOncology200569Suppl 3111616301831
   PubMed Web of Science ®Google Scholar
• MonkBJHanEJosephs-CowanCAPugmireGBurgerRASalvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerGynecol Oncol2006102214014416790264
   PubMed Web of Science ®Google Scholar
• PaleyPJStaskusKAGebhardKVascular endothelial growth factor expression in early stage ovarian carcinomaCancer1997801981069210714
   PubMed Web of Science ®Google Scholar
• SengerDRVan de WaterLBrownLFVascular permeability factor (VPF, VEGF) in tumor biologyCancer Metastasis Rev1993123–43033248281615
   PubMed Web of Science ®Google Scholar
• FerraraNMolecular and biological properties of vascular endothelial growth factorJ Mol Med (Berl)199977752754310494799
   PubMed Web of Science ®Google Scholar
• FerraraNRole of vascular endothelial growth factor in the regulation of angiogenesisKidney Int199956379481410469350
   PubMed Web of Science ®Google Scholar
• FerraraNVascular endothelial growth factor: molecular and biological aspectsCurr Top Microbiol Immunol19992371309893343
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic targetNature2005438707096797416355214
   PubMed Web of Science ®Google Scholar
• ShalabyFRossantJYamaguchiTPFailure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature1995376653562667596435
   PubMed Web of Science ®Google Scholar
• ZebrowskiBKLiuWRamirezKAkagiYMillsGBEllisLMMarkedly elevated levels of vascular endothelial growth factor in malignant ascitesAnn Surg Oncol19996437337810379858
   PubMed Web of Science ®Google Scholar
• ByrneATRossLHolashJVascular endothelial growth factortrap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer modelClin Cancer Res20039155721572814654557
   PubMed Web of Science ®Google Scholar
• XuLYonedaJHerreraCWoodJKillionJJFidlerIJInhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinasesInt J Oncol200016344545410675474
   PubMed Web of Science ®Google Scholar
• StoelckerBEchtenacherBWeichHASztajerHHicklinDJMannelDNVEGF/Flk-1 interaction, a requirement for malignant ascites recurrenceJ Interferon Cytokine Res200020551151710841080
   PubMed Web of Science ®Google Scholar
• KoboldSHegewisch-BeckerSOechsleKJordanKBokemeyerCAtanackovicDIntraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?Oncologist200914121242125120008305
   PubMed Web of Science ®Google Scholar
• NumnumTMRocconiRPWhitworthJBarnesMNThe use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecol Oncol2006102342542816797681
   PubMed Web of Science ®Google Scholar
• HamiltonCAMaxwellGLChernofskyMRBernsteinSAFarleyJHRoseGSIntraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancerGynecol Oncol2008111353053218561992
   PubMed Web of Science ®Google Scholar
• KestersonJPMhawech-FaucegliaPLeleSThe use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case reportGynecol Oncol2008111352752918710781
   PubMed Web of Science ®Google Scholar
• StewartMWGripponSKirkpatrickPAfliberceptNat Rev Drug Discov201211426927022460118
   PubMed Web of Science ®Google Scholar
• StewartMWAflibercept (VEGF trap-eye): the newest anti-VEGF drugBr J Ophthalmol3232012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• KimESSerurAHuangJPotent VEGF blockade causes regression of coopted vessels in a model of neuroblastomaProc Natl Acad Sci U S A20029917113991140412177446
   PubMed Web of Science ®Google Scholar
• HuangJFrischerJSSerurARegression of established tumors and metastases by potent vascular endothelial growth factor blockadeProc Natl Acad Sci U S A2003100137785779012805568
   PubMed Web of Science ®Google Scholar
• HuLHofmannJHolashJYancopoulosGDSoodAKJaffeRBVascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer modelClin Cancer Res20051119 Pt 16966697116203789
   PubMed Web of Science ®Google Scholar
• LockhartACRothenbergMLDupontJPhase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsJ Clin Oncol201028220721419949018
   PubMed Web of Science ®Google Scholar
• GayaATseVA preclinical and clinical review of aflibercept for the management of cancerCancer Treat Rev1192012 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• TengLSJinKTHeKFZhangJWangHHCaoJClinical applications of VEGF-trap (aflibercept) in cancer treatmentJ Chin Med Assoc201073944945620875616
   PubMed Web of Science ®Google Scholar
• ColomboNMangiliGMammolitiSA Phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascitesGynecol Oncol20121251424722112608
   PubMed Web of Science ®Google Scholar
• GotliebWHAmantFAdvaniSIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a Phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• RufPLindhoferHInduction of a long-lasting antitumor immunity by a trifunctional bispecific antibodyBlood20019882526253411588051
   PubMed Web of Science ®Google Scholar
• ZeidlerRMysliwietzJCsanadyMThe Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cellsBr J Cancer200083226126610901380
   PubMed Web of Science ®Google Scholar
• HeissMMMurawaPKoralewskiPThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trialInt J Cancer201012792209222120473913
   PubMed Web of Science ®Google Scholar
• HeissMMStrohleinMAJagerMImmunotherapy of malignant ascites with trifunctional antibodiesInt J Cancer2005117343544315906359
   PubMed Web of Science ®Google Scholar
• BurgesAWimbergerPKumperCEffective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II studyClin Cancer Res200713133899390517606723
   PubMed Web of Science ®Google Scholar
• PietznerKJagerMSchoberthAFirst patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case reportMed Oncol20122921391139621544631
   PubMed Web of Science ®Google Scholar
• El-ShamiKAEEl-KermYOpen-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascitesJ Clin Oncol20072518S620 Supplement9043
   Google Scholar